Skip to main content
SpringerLink
Log in

Current Status of Biosimilars in Oncology

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. It is estimated that the total market for cancer biologicals will reach approximately US$68 billion at that time. Approximately 20 biosimilars have entered the European market since the launch of the original approval guidelines in 2005, and four biosimilars have been approved in the USA since 2015. Data from European countries with the highest market entrance of biosimilars suggest that the incorporation of biosimilars into healthcare systems worldwide may result in a 30–45% cost savings. Initial levels of apprehension expressed by healthcare providers regarding the safety and efficacy of integrating biosimilars into the treatment of cancer patients have gradually decreased through active educational programs. The trust generated by regulatory agencies and drug manufacturers will ultimately make the adoption of biosimilars by healthcare providers and patients a smooth process. Future efforts to improve on the global acceptance and safety of biosimilars must include standardization of naming, regulatory requirements, and pharmacovigilance programs worldwide. High expectations are being placed on the cost savings, safety, and efficacy of these products. The entry costs for biosimilars and the pricing reaction of their originator products will determine the true savings by troubled health systems in dire need of cost cuts. This article discusses basic principles of biosimilars in hematology and oncology, the current status of their clinical development, and trends of acceptance by healthcare providers, and provides insight into potential future challenges.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Reproduced with permission from: Schneider [3]

Similar content being viewed by others

Notes

  1. Blockbusters are drugs that generate at least US$1 billion for the company that develops them.

  2. The biosimilar forum is a network of pharmaceutical companies including Allergan, Amgen, Boehringer-Ingelheim, Coherus, EMD-Serono, Merck, Pfizer, Samsung Bioepis, Sandoz, and Teva.

References

  1. Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice. Cancer Med. 2014;3(4):889–99. doi:10.1002/cam4.258.

    Article  PubMed  PubMed Central  Google Scholar 

  2. FDA. FDA 101: regulating biological products. 25 July 2008. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048341.htm. Accessed 15 Sept 2016.

  3. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–8. doi:10.1136/annrheumdis-2012-202941.

    Article  CAS  PubMed  Google Scholar 

  4. FDA. Frequently asked questions on patents and exclusivity. What is the difference between patents and exclusivity? 2014. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm. Accessed 15 Sept 2016.

  5. Generic Pharmaceutical Association. Generic drug savings in the U.S. Seventh annual edition: 2015. http://www.gphaonline.org/media/wysiwyg/PDF/GPhA_Savings_Report_2015.pdf. Accessed 16 Dec 2016.

  6. Camacho LH, Pai N. Pharmacovigilance of oncology biosimilars. J Pharmacovigil. 2015;S3(001):1–6. doi:10.4172/2329-6887.S3-001.

    Google Scholar 

  7. GaBi. WHO definitions of biosimilars. In: Generics and Biosimilars Initiative Journal (GaBI Journal). gabionline.net. 2012. http://gabionline.net/Biosimilars/General/WHO-definitions-of-biosimilars. Accessed 21 Sept 2016.

  8. FDA. Nonproprietary naming of biological products - guidance for industry. 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.pdf. Accessed 13 Oct 2016.

  9. FDA. Guidance for industry - reference product exclusivity for biological products filed under Section 351(a) of the PHS Act. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm407844.pdf. Accessed 30 Sept 2016.

  10. FDA. Scientific considerations in demonstrating biosimilarity to a reference product. FDA, 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 26 Oct 2016.

  11. FDA. Guidance for industry - clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2014. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf. Accessed 1 March 2017.

  12. WHO. Essential medicines and health products - pharmacovigilance. 2016. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/. Accessed 4 Oct 2016.

  13. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy—principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.

    Google Scholar 

  14. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol. 2011;86(4):277–88. doi:10.1111/j.1600-0609.2010.01566.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. FDA. Interferon alfa-2b package insert. In: FDA approved drug products. 1986. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory-labelinfo. Accessed 16 Sept 2016.

  16. FDA. Filgrastim package insert. 2014. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory-labelinfo. Accessed 26 Sept 2016.

  17. EMA. European Medicines Agency biosimilar approvals guidelines. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed 12 Dec 2016.

  18. Biosimilar N. 10 years of biosimilar medicines in Europe: transforming healthcare. 2016. http://www.biosimilarnews.com/10-years-of-biosimilar-medicines-in-europe-transforming-healthcare. Accessed 28 Nov 2016.

  19. Troy DE. Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) testimony before the Senate Committee on the Judiciary. 1 Aug 2003. Updated 24 Jul 2009. https://www.fda.gov/newsevents/testimony/ucm115033.htm. Accessed 12 April 2017.

  20. FDA. Biosimilars implementation. In: Committee on Energy and Commerce-Subcommittee on Health-United States House of Representatives. FDA, 2016. http://www.fda.gov/newsevents/testimony/ucm485042.htm. Accessed 12 Sept 2016.

  21. WHO. Guidelines on the use of International Nonproprietary Names (INNs) for pharmaceutical substances. Geneva: Programme on International Nonproprietary Names (INN); 1997. http://apps.who.int/medicinedocs/pdf/h1806e/h1806e.pdf. Accessed 21 Nov 2016.

  22. WHO. Guidance on INN. WHO, 2015. http://www.who.int/medicines/services/inn/innguidance/en/. Accessed 11 Oct 2016.

  23. Murphy B. Debate over naming of biosimilars intensifies ahead of WHO meeting. Pharm J. 2015;294(7866). doi:10.1211/PJ.2015.20068663.

  24. Brennan Z. FDA calls on companies to select 10 suffixes for biosimilar, biologic names. Rockville: Regulatory Affairs Professionals Society (RAPS); 2016.

    Google Scholar 

  25. Siegel JF, Fischer A. Ten years of biosimilars in Europe. Biologics Blog. 2015 Dec 8. http://www.biologicsblog.com/ten-years-of-biosimilars-in-europe/. Accessed 12 April 2017.

  26. EMA. Guideline on similar biological medicinal products. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 16 Nov 2016.

  27. Genentech. Trastuzumab: package insert and prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103792s5327lbl.pdf. Accessed 6 Nov 2016.

  28. GaBI. Celltrion submits trastuzumab biosimilar application to EMA. Generics and Biosimilars Initiative. 2016. http://www.gabionline.net/Biosimilars/News/Celltrion-submits-trastuzumab-biosimilar-application-to-EMA. Accessed 21 Nov 2016.

  29. Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Heritage: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin [abstract no. LBA503]. J Clin Oncol. 2016;34 suppl.

  30. Yin D, Barker KB, Li R, Meng X, Reich SD, Ricart AD, et al. A phase I pharmacokinetics trial comparing PF-05280014 (a potential biosimilar) and trastuzumab in healthy volunteers (REFLECTIONS B327-01) [abstract no. 612]. J Clin Oncol. 2013;31 suppl.

  31. Stenina MB, Ignatova E, Frolova MA, Burdaeva ON, Nechaeva MP, Kopp MV, et al. Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients [abstract no. e11576]. J Clin Oncol. 2014;32 suppl.

  32. Genentech. Rituximab: package insert-prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf. Accessed 16 Nov 2016.

  33. GaBI. Biosimilars of rituximab. In: Generics and Biosimilars Initiative Journal (GaBI Journal). 2015. http://gabionline.net/Biosimilars/General/Biosimilars-of-rituximab. Accessed 21 Nov 2016.

  34. Genentech. Bevacizumab: package insert-prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s305lbl.pdf. Accessed 16 Nov 2016.

  35. Thatcher N, Thomas M, Paz-Ares L, Ostoros G, Pan Z, Goldschmidt JH, et al. Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC [abstract no. 9095]. J Clin Oncol. 2016;34 suppl.

  36. GaBI. Biosimilars of Bevacizumab. In: Generics and Biosimilars Initiative Journal (GaBI Journal). 2016. http://www.gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab. Accessed 25 Nov 2016.

  37. Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Cancer Netw. 2011;9(Suppl 4):S1–22.

    Article  CAS  Google Scholar 

  38. Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33(12):2160–72. doi:10.1007/s12325-016-0431-5.

    Article  PubMed  Google Scholar 

  39. GaBI. Biosimilars approved in Europe. GaBI; 2016. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed 28 Nov 2016.

Download references

Author information

Authors and Affiliations

  1. Center for Oncology and Blood Disorders, 6560 Fannin St. Suite 1224, Houston, TX, 77030, USA

    Luis H. Camacho

Authors
  1. Luis H. Camacho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis H. Camacho.

Ethics declarations

Funding

Dr. Camacho receives research funds from Macrogenics, Inc.

Conflicts of Interest

Dr. Camacho is a member of the bureau of speakers of Amgen, Merck, and Lexicon.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Camacho, L.H. Current Status of Biosimilars in Oncology. Drugs 77, 985–997 (2017). https://doi.org/10.1007/s40265-017-0743-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0743-z

Keywords

Search

Navigation